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Non-coding RNANotch signaling plays a pivotal role in embryonic and postnatal development.
Upon binding of a Notch ligand, proteolytic cleavage events liberate the Notch-intracellular domain (NICD) that
migrates into the nucleus. In order to activate target genes, NICD associates with the transcription factor RBP-J
(also known as CSL), Mastermind and the acetyltransferase p300.
Here, we identify the DEAD-box RNA helicase Ddx5 as a novel component of the RBP-J/NICD complex utiliz-
ing a biotinylation-tagging approach followed by mass-spectrometry. Biochemical assays conﬁrm a direct in-
teraction of Ddx5 with RBP-J. We show that Ddx5 localizes at RBP-J binding sites within the Notch target
genes preTCRα, Hes1 and CD25 in a Notch-dependent manner. Moreover, knockdown of Ddx5 also
downregulates a subset of Notch target genes in a murine pre T-cell model. Interestingly, also knockdown/
overexpression of the RNA coactivator SRA, a cofactor of Ddx5, downregulates Hes1 and preTCRα. Using
Chromatin-IP, we show that this effect is accompanied with a loss of p300 occupancy at Notch target genes
and decreased histone acetylation. Together, our data demonstrate that Ddx5 and SRA function as
coactivators of Notch signaling.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The Notch signaling pathway is an evolutionarily conserved path-
way that plays pivotal roles in many cellular and developmental pro-
cesses. Notch signaling is activated upon cell-to-cell contact as a
result of interactions between Notch receptors and their ligands
(Delta or Jagged). This promotes two proteolytic cleavage events of
the Notch receptor [1]. The extracellular cleavage is catalyzed by
ADAM-metalloproteases, followed by the intracellular cleavage medi-
ated by a γ-secretase containing complex. The second cleavage re-
leases the Notch intracellular domain (NICD), which translocates
into the nucleus to activate the transcription of its targets [2]. The
NICD cannot directly bind to DNA but heterodimerizes with the
DNA binding protein RBP-J (recombination signal binding protein
Jκ also called CSL or CBF1) [3] activating the transcription of genes
containing RBP-J binding sites. The interaction of NICD with RBP-J
creates an interface that is recognized by the essential coactivator
MAML [4] reviewed in [5]. The RBP-J/Notch/Mastermind coactivatorrggrefe).
l rights reserved.complex can subsequently recruit the histone acetyltransferase
p300 or PCAF [6,7].
Biochemical studies by Capobianco and colleagues showed that
the Notch-coactivator is a high molecular weight complex of
1.5 MDa in size, suggesting that there are additional, yet unknown
coactivator components [8]. The importance of MAML has been
shown with dominant-negative MAML, which completely blocks
Notch-mediated transcriptional activation [9]. In addition, several
kinases and the ubiquitin ligase Fbw7 destabilize this complex,
which is important not only during development, but also during car-
cinogenesis [10].
Ddx5/p68 is an active DEAD-box containing RNA helicase that has
been proposed to play a tumor-promoting role and has been described
as a transcriptional coactivator and a splicing factor, reviewed in
[11,12]. Ddx5 expression appears to be ubiquitous but expression levels
vary considerably between tissues. A closely related RNA helicase,
Ddx17, forms heterodimers with Ddx5. Ddx5 has been described as an
important coactivator of estrogen-receptor alpha where it interacts
with a long non-coding RNA called steroid receptor RNA activator
(SRA) [13,14]. Interestingly, Ddx5 together with SRA also interact with
CCCTC-binding factor (CTCF) and cohesins [15].
In this study, we show that Ddx5 is found in complex with the
RBP-J/Notch coactivator complex and is required for transcriptional
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Fig. 1. Ddx5 physically interacts with the RBP-J/Notch complex in vivo and in vitro. A. Notch and Ddx5 interact in coimmunoprecipitation experiments: biotin-tagged Notch intra-
cellular domain (NICD) was expressed in preT-cells called Beko. Streptavidin magnetic beads were used to pulldown Notch-ICD coactivator complex. Precipitated proteins were
analyzed by Western blot using streptavidin-HRP detecting Notch-ICD (upper panel), α-RBP-J (middle-panel) and α-Ddx5 antibodies (lower panel). In lane 4 Ddx5 co-puriﬁes
with biotin-NICD. B. Ddx5 and RBP-J interact in coimmunoprecipitation experiments: Beko cells expressing biotin-tagged Ddx5 were subjected to streptavidin pulldown. Ddx5
was detected by Western blotting with Strep-HRP (upper panel) and endogenous RBP-J with α-RBP-J antibodies (lower panel, lane 4). As control cells for A and B, Beko cells ex-
pressing the biotin ligase (BirA)-only were used and the in vivo biotinylated background proteins (carboxylases) are marked with asterisks. C. RBP-J and Ddx5 interact in GST
pull-down experiments: Cell-free synthesized 35S-labeled Ddx5 binds to GST-RBP-J immobilized to glutathione-Sepharose beads (upper panel, lane 3), but not to GST only. As pos-
itive control the interaction of RBP-J with NICD-OP (Notch intracellular domain with OPA and PEST (OP) domain) was examined (lower panel, lane 3).
1181C. Jung et al. / Biochimica et Biophysica Acta 1833 (2013) 1180–1189activation of several Notch target genes. In addition, we reveal that
the non-coding RNA SRA plays a similar role and is required for the
recruitment of histone acetyltransferase p300 to Notch target genes.
2. Material and methods
2.1. Reagents, antibodies and cell culture
For ChIP experiments, the following antibodies were used: H3K18ac
(Cell Signaling, 9675), H3 (Abcam, ab1791), p300 (Santa Cruz Biotech-
nologies, sc-585), Ddx5 (Diagenode, PAb 204). ForWestern blotting, the
following antibodies were used: RBP-J (Cosmo Bio Co., Clone T6709;
secondary:α-rat IgG [Dianova]), Ddx5 (Diagenode, PAb 204), GAPDH(glyceraldehyde-3-phosphate dehydrogenase) (Abcam, ab8245), RNA
pol II (N-20) (Santa Cruz Biotechnology, sc-899),α-Flag (M5 monoclo-
nal, Sigma, F4042), secondary: anti-mouse IgG (Amersham Biosciences,
NA931), α-rabbit IgG (Cell Signaling, 7074).
Mouse pre-T cells (Beko) were grown in Iscove's modiﬁed Dulbecco
medium (Gibco) with 2% fetal calf serum FCS (Pan-Biotech), 1% nones-
sential amino acids (Gibco), 0.3 mg/L Primatone (Quest), 1% penicillin/
streptomycin (Gibco) and 5 mg/L insulin (Sigma). The cell line was
maintained at 37 °C under 5% CO2. The cells were treated with GSI
(10 μg/mLDAPT; Calbiochem(565770) or DMSOonly. For tamoxifen in-
duction, the cells were treated with 0.75 μg/mL 4-OHT (Sigma, H7904)
or 100% ethanol as control [16]. HeLa cells (ATCC CCL 2) were grown
in Dulbecco's modiﬁed eagle medium (DMEM, Gibco) supplemented
AB
D
C
co
ntr
ol
RB
P-
J K
O
pro B cells
α-GAPDH
α-RBP-J
(kDa)
43
34
72
55 *
RB
P-J
re
la
tiv
e 
ex
pr
es
sio
n 
le
ve
l
control
RBP-J KO
HP
RT
0
0.2
0.8
1
1.2
0.6
0.4
pre
TC
Rα
+1
0.5
kb He
s1
+0
.6k
b CD
25
-
26
kb
0
0.005
0.01
0.015
0.02
0.025
0.03
0.035
0.04
0.045
0.05
pr
ec
en
t o
f i
np
ut
mock DMSO
α-Ddx5 DMSO
mock GSI
α-Ddx5 GSI
co
ntr
ol
control Hes1
+0.6 kb
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0.16
pe
rc
en
t o
f i
np
ut
mock control
α-Ddx5 control
mock RBP-J KO
α-Ddx5 RBP-J KO
Fig. 2. Ddx5 localizes at enhancer elements of Notch target genes in a Notch- and RBP-J dependent manner. A. Chromatin-immunoprecipitation (ChIP) with α-Ddx5 antibody. Only
in the active state (DMSO control) is Ddx5 localized at enhancer elements of Notch target genes preTCRα (+10.5 kb), Hes1 (+0.6 kb) and CD25 (−26 kb) (light gray bars). Data
were normalized to GAPDH promoter region, for which no occupancy was observed; the Hes1 region +2.4 kb served as an additional control. Upon inhibition of Notch by treat-
ment with γ-secretase inhibitor DAPT for 24 h, Ddx5 occupancy is undetectable (dark gray bars) (mean±SD, n=3). B. RBP-J transcript is downregulated in RBP-J deﬁcient
proB-cells. The knockout (KO) of RBP-J is induced upon tamoxifen treatment. Upon tamoxifen treatment of RBP-Jﬂox/ﬂox x Cre-ER proB-cells, the mRNA level of RBP-J is severely
diminished (black bars) compared with control (ethanol treated cells, gray bars) and housekeeping gene HPRT. The data are normalized versus the housekeeping gene TBP.
Data presented as means±SD of three independent experiments measured in duplicates. C. RBP-J protein is lost in RBP-J deﬁcient proB-cells. Using RBP-J speciﬁc antibody in West-
ern blot the RBP-J protein disappears in RBP-J knock out cells (lower panel) compared with GAPDH control (upper panel). Background bands are labeled with asterisks. D. Ddx5
binding at Hes1 Notch target gene is RBP-J dependent. ChIP experiments in RBP-J knock out (KO) proB-cells were performed using α-Ddx5 antibody. When RBP-J is deleted,
Ddx5 no longer binds to the Hes1 enhancer region +0.6 kb. ChIP was normalized to GAPDH promoter region and as control the Hes1 region +2.4 kb was analyzed. Values are
presented as mean±SD for duplicate samples from a representative experiment; the experiment was repeated three times.
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was maintained at 37 °C under 5% CO2. Pro-B cells from RBP-Jﬂox/ﬂox
×Cre-ER mice were established by culturing bone marrow cells for
14 days in IL-7–supplemented Iscove's medium (Biochrom) con-
taining 10% FCS (Pan-Biotech), 2 mM L-glutamine, 100 U/ml penicillin,
100 U/ml streptomycin (Invitrogen) and 5×10−5 M 2-mercaptoethanol.
The cells were maintained at 37 °C under 7.5% CO2. For IL-7–dependent
growth, the supernatant of J558L cells stably transfected with a vector
encoding mouse IL-7 was supplemented in excess.
Mouse Ddx5 was ampliﬁed using Beko preT cell cDNA and the fol-
lowing primers (forw: GCGGCCGCTATATCGAGTTATTCTAGTGACCGA
GACCGCGGCC, rev: GCGGCCGCTTATTGAGAATACCCTGTTGGCATGG
GATAG). The resulting fragment was cut with NotI and ligated into0
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Fig. 3. Ddx5 acts as a coactivator in Notch signaling. A and B. Ddx5 acts as a coactivator in N
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pSCT-SRAhuman was used as a template for ampliﬁcation with
following primers (forw: CCTCGAGGGCAACAAGGAACGCGGCT, rev:
TTTCAATAAAAACATCTCTGCGGGCGGCCGCC). The resulting fragment
was cut with XhoI, NotI and ligated into the retroviral vector
pLxsp-puro. The retroviral pMIGRFlagNotchER plasmid, the GST-
RBP-J and the pcDNA3.1-RBP-J fragments (NTD, BTD, CTD) were de-
scribed previously [16].
2.2. Retroviral infection of Beko cells
Ecotropic-Phoenix cells were transfected with calcium phosphate
method. Therefore Phoenix cells were pre-treated with 25 μM chloro-
quine for 5 min. For transfection 1 ml 2× HBS (pH 7.05), 124 μl 2 M
CaCl2, 20 μg DNA up to 1 ml with ddH2O were transferred onto the
cells, mixed thoroughly and incubated over night. The next day fresh
medium was loaded onto the cells. After 24 h incubation Beko cells
were retrovirally infected using supernatants from Ecotropic-Phoenix
packaging cells, supplemented with polybrene at 2 mg/ml. Retroviral
gene expression was monitored using ﬂow cytometry to measure
co-expressed ﬂuorescent proteins. Where necessary, cells were sorted
to obtain pure populations with equivalent expression levels.
2.3. Knockdown in Beko cells
For knockdownof Ddx5 and SRA the Lentiviral Harvard shRNA (TRC1)
library was used with the following target sequences in the vector back-
bone pLKO.1-puro: Ddx5 shRNA1 (CGGGAAGCTAATCAAGCAATT), Ddx5
shRNA2 (GCGAATGTCATGGATGTGATT), SRA (CAGACTCACTTCACCTGA
CTT) and scrambled shRNA was used as control. For transfection, 293 T
cells were incubated 6 h together with 30 μl Lipofectamine-2000 reagent
(Invitrogen), 3.3 μgDNA (pLKO.1-puro) andwith the lentiviral packaging
vectors psPAX (2.5 μg) and pMD (1 μg). After 48 h incubation the super-
natant from 293T cells was added to the Beko cells for the lentiviral infec-
tion. The puromycin selection was carried out 24 h after infection by
adding 2 μg/ml puromycin to the cells.
2.4. RNA extraction, RT–PCR and quantitative PCR
Total RNA was isolated from Beko cells using Trizol reagents
(Ambion, 15596018). For cDNA synthesis, 1 μg of RNAs was reverse
transcribed using randomhexamers and reverse transcriptase according
to the manufacturer's protocol (Thermo Scientiﬁc, K1622). Real-time
PCR reactions were performed using a 7300 ABI PRISM sequence detec-
tor system (Applied Biosystems) according to the manufacturer's rec-
ommendations. Quantitative PCRs were performed using ABsolute
QPCR ROX mix (Thermo Scientiﬁc, no. AB-1139), gene-speciﬁc oligonu-
cleotides (see Supplementary material) and double-dye probes under
the following conditions: 2 min at 50 °C and 15 min at 95 °C, and then
45 cycles of 15 sec at 95 °C and 1 min at 60 °C.
For RNA immunoprecipitation experiments quantitative PCRs were
performed using ABsolute QPCR SYBR Green ROX mix (ThermoFig. 4. The non-coding RNA SRA has distinct effects inNotch signaling. A and B: SRA associatesw
from Beko preT cells stably transfected with biotin-tagged Ddx5 were used in streptavid
streptavidin-HRP (biotin tagged-Ddx5, upper panel) and anti-RBP-J antibody (lower panel), o
and HPRT (mean±SD, n=3). As control cells, preTcell line Beko expressing biotin ligase (BirA
with an asterisk. C and D: SRA associates with Notch in native RNA-immunoprecipitation (nR
human SRA were treated 24 h with tamoxifen (4-OHT) or ethanol (ET-OH) as control. Nuclear
by immunoblottingwith anti-Flag antibody (Flag tagged-Notch) orD, total RNAwas extracted a
was normalized to control HPRT. E and F: The long noncoding RNA SRA facilitates Ddx5/Notch
was transfected alone or together with expression plasmids (25 ng) for themurine Notch intra
and increasing amounts of empty pSCT vector or pSCT-SRA (100 ng, 200 ng, 300 ng) intoHeLa c
independent experiments are shown (mean±SD, n=4). G. Knockdown of the long non coding
transcripts in SRA-depleted (black bars) Beko preT cells compared with control scrambled
downregulated whereas CD25 is upregulated. Data was normalized to TBP (mean±SD, n=3
RNA was extracted from Beko preT cells stably transfected with SRA mouse (light gray bars)
were downregulated whereas CD25 remained unchanged compared with empty vector controScientiﬁc, no. AB-1163) under the following conditions: 2 min at
50 °C and 15 min at 95 °C, and then 50 cycles of 15 sec at 95 °C,
30 sec at 60 °C and 1 min 70 °C followed by dissociation. The results
were normalized to endogenous TBP (TATA-binding protein)mRNA ex-
pression level.
2.5. ChIP
Ddx5, p300 and H3K18ac ChIP experiments were performed via
cross-linking ChIP using the protocol provided by Upstate Biotechnol-
ogy with minor modiﬁcations. Brieﬂy, Beko cells were ﬁxed with 1%
formaldehyde for 10 min at room temperature. The cross-linking re-
action was stopped with 125 mM glycine. Chromatin was prepared
by using a cell lysis buffer (1% SDS, 50 mM Tris–HCl at pH 8.0,
10 mM EDTA, 2 mm dithiothreitol) and sonicated. Chromatin was
5-fold diluted with dilution buffer (16.7 mM Tris–HCl at pH 8.0,
167 mM NaCl, 1.2 mM EDTA, 1% Triton X-100) and precleared with
presaturated Protein A beads. The precleared chromatin extract was
incubated overnight with the appropriate antibody and 50 μl were
collected as input control. The immunoprecipitates were immobilized
on protein A-Sepharose beads for 1 h. After washing the beads with
150 mM NaCl, 500 mM NaCl and 0.25 M LiCl-containing buffers,
chromatin was eluted from the beads with elution buffer (0.1 M
NaHCO3, 1% SDS) at 25 °C shaking. The cross-linking of chromatin
was reversed for 6 h at 65 °C in the presence of 200 mM NaCl. Chro-
matin was dissolved in Tris–EDTA buffer (40 mM Tris–HCl at pH 6.5,
20 mM EDTA), and treated with proteinase K for 1 h at 45 °C. After
puriﬁcation by phenol-chloroform extraction, the chromatin was pre-
cipitated overnight at −20 °C in the presence of tRNA, glycogen and
isopropanol. The enriched chromatin was analyzed by quantitative
real time PCR. The values were calculated as percent of the input.
2.6. Preparation of nuclear cell extracts
Tenmillion cells werewashed three times in PBS and pelleted by cen-
trifugation at 300 g. The pellet was resuspended in 1 ml of ice-cold hypo-
tonic buffer (20 mM Hepes, 20 mM NaCl, 5 mM MgCl2, 0.2 mM PMSF)
incubated 20 minon ice andvortexed20 s afterwards. After 5 min centri-
fugation at 20,000 g the pellet was washed once in PBS and resuspended
in 100 μl hypertonic buffer (0.2% NP-40, 20 mM Hepes, 300 mM KCl,
1 mM MgCl2 1 mM Dithiothreitol (DTT), 1× Proteaseinhibitor (Roche)
and0.2 mMphenylmethylsulfonyl-ﬂuoride (PMSF). After 20 min incuba-
tion the lysate was cleared at 80,000 g for 30 min. Protein concentrations
were determined by the Bradford assay (Bio-Rad) and extractswere used
for immunoprecipitation, RNA-immunoprecipitation and for Western
blotting.
2.7. Streptavidin-immunoprecipitation
Immunoprecipitation experiments were carried out using nuclear
extract from Beko preT cells. 500 μg extracts were incubated with
10 μl streptavidine magnetic beads (Dynabeads M-280, Invitrogenith Ddx5 in native RNA-immunoprecipitation (nRNA-IP) experiments. A. Nuclear extracts
in coimmunoprecipitation experiments and either analyzed by immunoblotting with
r B, total RNA was extracted and subjected to qRT-PCR with the primers speciﬁc for SRA
) were used and the in vivo biotinylated background proteins (carboxylases) are marked
NA-IP) experiments. C. Beko preT cells stably transfected with Flag-tagged NICD-ER and
extracts were prepared and used in Flag-immunoprecipitation experiments and analyzed
nd subjected to qRT-PCRwith the primers speciﬁc for human SRA (mean±SD, n=3). Data
/RBP-J dependent transcription. A Notch responsive reporter construct [pGa981/6, (1 μg)]
cellular domain [(NICD, (E)], RBP-VP16 (F) and expression plasmid for Ddx5(wt) (200 ng)
ells. Promoter activitywas analyzed 24 hours after transfection.MW, SD from at least four
RNA SRA leads to slight downregulation of several Notch target genes. qRT-PCR analysis of
shRNA (light gray bars). The Notch target genes preTCRα, Hes1 and Notch1 are slightly
). H. Overexpression of SRA leads to downregulation of several Notch target genes. Total
or SRA human (black bars) plasmids. The Notch target genes preTCRα, Hes1 and Notch1
l (white bars). Data was normalized to TBP (mean±SD, n=3).
1186 C. Jung et al. / Biochimica et Biophysica Acta 1833 (2013) 1180–1189112.06) for 2 h at 4 °C. The beads were washed six times with
streptavidin washing buffer (TBS 1×, 250 mM NaCl, 0.2% NP-40)
and were resuspended in SDS-polyacrylamide gel loading buffer.2.8. Western blotting
The proteins resolved in SDS-polyacrylamide gels (6–12%) were
transferred electrophoretically for 1 h at 4 °C temperature to nitrocel-
lulose membranes (Whatman) at 380 mA by using a Tris–glycine
buffer system. The membranes were preblocked for 1 h in a solution
of 5% milk powder in PBS before the antibodies were added.2.9. GST pull-down assay
Proteins were translated in vitro in the presence of
35
S methionine
using the reticulocyte lysate-coupled transcription/translation sys-
tem (Promega). Translation and labeling quality were monitored by
SDS-PAGE. The GST fusion proteins were expressed in Escherichia
coli strain BL21 (Stratagene) and stored as whole bacterial lysates at
−80 °C. Approximately, 3 μg of GST protein and GST fusion protein
were immobilized with glutathione–Sepharose beads (GE Healthcare,
no. 17-5132-01) and incubated together with the in vitro translated
proteins in buffer A (40 mM Hepes at pH 7.5, 5 mM MgCl2, 0.2 mM
EDTA, 0.5% Nonidet P40 [NP-40], 100 mM KCl) under rotation for
1 h at 4 °C. Beads incubated with in vitro translated Ddx5 were
washed two times with 600 μl of buffer B (equivalent to buffer A,
but containing 300 mM KCl) and two times with 600 μl of buffer C
(equivalent to buffer A, but containing 500 mM KCl). Beads incubated
with in vitro translated NICD-OP (Notch intracellular domain with
OPA and PEST (OP) domain) were washed two times with 600 μl of
buffer A and two times with 600 μl of buffer B [18]. As control
100 U Benzonase (Novagen, 70746) and 100 U RNase (Stratagene,
400720) were added to the 1 h binding reaction.2.10. Native RNA-immunoprecipitation (nRNA-IP)
Beko preT cells were transfectedwith biotin-taggedDdx5 and nucle-
ar extractwas prepared. For puriﬁcation 5 mgextractwas incubated 2 h
with streptavidin magnetic beads. The beads were washed 4 times with
RIP washing buffer (50 mM Tris–HCl pH 7.5, 750 mM NaCl, 1 mM
MgCl2, 0.05% NP-40) and afterwards resuspended in 100 μl RIPwashing
buffer. 10 μl was used forwestern blot analysis and resuspended in 10 μl
SDS-polyacrylamide gel loading buffer. The other 90 μl were incubated
for 30 min 55 °Cwith 1% SDS and 30 μg proteinase K. The RNA puriﬁca-
tion was carried out using the Qiagen RNeasy Kit (Cat. no. 74134) and
cDNA synthesis was performed with the Thermo Scientiﬁc Kit
(RevertAid M-MuLV Reverse Transcriptase K1629). Beko preT cells
transfected with FlagNotchER and human SRA were treated 24 h with
4-OHT and nuclear extract was prepared. For puriﬁcation 5 mg extract
was incubated 2 h with α- Flag M2 Agarose beads (Sigma A2220) and
washed 6 times with RIP washing buffer. The following procedure was
done like above.2.11. Luciferase assay
HeLa cells (5×104) were transfected in 24-well plates (Nunc)
with 1 μg of reporter plasmid pGa981/6 [19,20] alone or together
with various amounts of expression plasmid (given in the corre-
sponding ﬁgure legends). Luciferase activity was determined from
four independent experiments 24 h after transfection with an LB
9501 luminometer (Berthold) using the luciferase assay system
from Promega.3. Results
3.1. RNA helicase Ddx5 physically interacts with the RBP-J/NICD complex
In order to identify Notch-intracellular domain (NICD) coactivator
components, we isolated NICD-containing complexes taking a
biotinylation tagging approach [21]. Using extracts from pre T-cells
infected with bio-NICD, Notch-containing complexes were puriﬁed in
a single-step procedure using streptavidin magnetic beads followed
by mass-spectrometric analysis. Notch1, Notch2, Mastermind-1,
Mastermind-3 and Dtx-2 peptides as well as a novel coactivator
component, RNA helicase Ddx5, were present in pulldowns with
streptavidin beads. Interestingly, Ddx5 has been previously identiﬁed
to form a complex with p300 acetyltransferase [22] a known compo-
nent of the Notch coactivator complex [6]. Mass-spectrometric results
were validated by co-immunoprecipitation experiments (Fig. 1A) and
GST-pulldown experiments (Fig. 1C and Fig. S1). After streptavidin
pulldown using nuclear extracts from bio-NICD expressing cells,
Notch-1 was detected in Western blotting using a streptavidin-HRP
(Fig. 1A, upper panel, lane 4). In addition to NICD, endogenous RBP-J
(middle panel) and Ddx5 (lower panel) were detected using α-RBP-J
and α-Ddx5 antibodies. In the reverse pulldown experiment using
nuclear extracts from bio-Ddx5 expressing pre-T cells, we could detect
endogenous RBP-J (Fig. 1B, lower panel, lane 4). We further tested the
physical interaction between Ddx5 and RBP-J in GST pulldown experi-
ments. In vitro transcribed full-length Ddx5 readily interacts with bac-
terially expressed GST-RBP-J but not with GST only (Fig. 1C). We
mapped the RBP-J/Ddx5 interaction extensively on both sides using fur-
ther GST-pulldown experiments (Fig. S1). Fragments of Ddx5 fused to
GST (GST-Ddx5 2–80, 282–388 and 387–500) interact with in vitro
transcribed/translated RBP-J (Fig. S1A). When using fragments of
RBP-J, the NTD- and BTD-domains but not the CTD domain interact
with Ddx5 (Fig. S1B and C). Furthermore, we could show that addition-
al RNase/DNase treatment has no effect on the interaction of Ddx5 and
GST-RBP-J (Fig. S2A and B). Together, our data support the notion that
Ddx5 is a novel component of the RBP-J/NICD coactivator complex.
3.2. RNA helicase Ddx5 is found at Notch target genes in vivo
To study Ddx5 recruitment at Notch target genes, we used a sponta-
neous T-cell lymphoma line from TCR-β knockout (Beko) mice as our
experimental model system [16]. We compared Beko cells untreated
(Notch-on) and Beko cells treated with γ-secretase inhibitor (GSI) for
24 h (Notch-off). In ChIP-experiments we detected strong binding of
Ddx5 to RBP-J/NICD binding sites of the genes preTCRα- (+10.5 kb),
Hes1 (+0.6 kb) and CD25 (−26 kb) (Fig. 2A). The RBP-J/Notch binding
sites are based on ChIP data followed by deep sequencing [23]. Impor-
tantly, Ddx5 binds in a Notch-dependent manner, since no binding is
observed upon switching-off Notch signaling with GSI (Fig. 2A). In
order to verify whether or not Ddx5 recruitment depends on RBP-J,
we established a pro-B cell line from RBP-J conditional knockout mice
[24] that carry Cre-recombinase transgene fused to the ligand-binding
domain of the estrogen receptor, Cre-ER (Fig. 2B–D). By adding tamox-
ifen, Cre-ER translocates to the nucleus, deleting the exons of RBP-J
encoding for the DNA binding domain. RNA and protein expression of
RBP-J is lost upon Cre-induction by tamoxifen [25] (Fig. 2B and C). Al-
though Hes1 expression was unaffected in RBP-J knockout B-cells
(data not shown), we could observe a strong decrease in Ddx5 binding
at the RBP-J enhancer site of Hes1 (+0.6 kb) (Fig. 2D). Ddx5 binding
was not observed at +2.4 kb in the Hes1 or at the GAPDH promoter
(Fig. 2D).
3.3. RNA helicase Ddx5 acts as a co-activator in Notch signaling
To analyze the function of Ddx5 in Notch/RBP-J dependent tran-
scription we ﬁrst performed reporter gene assays using the Notch-
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co-transfection of both, NICD (Fig. 3A) as well as RBP-VP16 (Fig. 3B)
resulted in a clear induction of promoter activity. Increasing amounts
of Ddx5(wt) led to a further increase of luciferase activity. Interest-
ingly, the helicase dead Ddx5 mutant [Ddx5(K144N)] also further in-
creased the pre-activated luciferase activity, although to a lesser
amount in RBP-VP16 dependent transcription (Fig. 3B). This is in
agreement with data analyzing the role of Ddx5 in ERα-Runx2- and
p53-mediated transcriptional transactivation [14,27,28]. In order to
investigate the role of Ddx5 at endogenous Notch target genes, we
generated Ddx5 knockdown cells (Fig. 3C and D, S3A and B). Ddx5
protein levels were signiﬁcantly downregulated as demonstrated in
Western blotting using α-Ddx5 antibodies whereas control antibod-
ies, RNA polymerase II showed no changes (Fig. 3C); similarly Ddx5A
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α-p300 SRA shRNAmRNA is downregulated (Fig. 3D). Notch target genes preTCRα,
Notch1, Hes1 and CD25 are downregulated in Ddx5 knockdown
cells, further supporting that Ddx5 functions as a coactivator for
Notch (Fig. 3D and Fig. S3B).
3.4. The long non-coding RNA SRA associates with Ddx5 and Notch-ICD
in T-cells and is a positive regulator of Notch signaling
Previous studies have shown that Ddx5 interacts with the long
non-coding RNA SRA [14]. Using bio-Ddx5 expressing cells, we
could observe that not only RBP-J is precipitated (Fig. 4A) but also
the long non-coding RNA SRA (Fig. 4B) as demonstrated by native
RNA immunoprecipitation. Importantly, in RNA immunoprecipitation
experiments using FlagNotchER we observed a tamoxifen-dependent
complex formation of Notch and SRA (Fig. 4C and D). This suggests
that Ddx5 and SRA are part of the RBP-J/NICD complex.
Using reporter gene assays in HeLa cellswe observed an SRA speciﬁc
activation of Ddx5/NICD/RBP-J dependent transcription (Fig. 4E and F).
Coexpression of Notch-ICD (Fig. 4E) or RBP-VP16 (Fig. 4F) togetherwith
a modest amount of Ddx5 (200 ng) revealed a slight increase of report-
er gene activity (comparewith Fig. 3A and B). Transcriptional activation
was further enhanced by increasing amounts of SRA expression, but not
by the empty vector (pSCT). Importantly, the expression of endogenous
SRA is not affected upon knockdown of Ddx5 (Fig. S3C).
Subsequently,we investigated the role of non-codingRNASRA in pro-
moting activation of Notch target genes. Therefore, we knocked-down
SRA in Beko cells and observed a decrease in expression of preTCRα,
Notch1 and Hes1 (Fig. 4G). Surprisingly, overexpression of either
human or mouse non-coding RNA SRA also leads to a downregulation
of preTCRα, Notch1 and Hes1 (Fig. 4H). One possible scenario is a
squelchingmechanism, inwhich overexpressed SRA titrates away an im-
portant cofactor for Notch. The negative squelching effect was initially
described for Gal4-mediated transcriptional activation in yeast [29].
Overexpression of one transcriptional activator is able to sequester a lim-
iting factor leading to repression rather than activation. Subsequently,
similar effects were described in higher eukaryotes, i.e. for cFos-Jun [30]
and p63 [31].
3.5. Occupancy of p300 andhistone acetylation is lost upon SRA knockdown
and overexpression at Notch target genes
We investigated the possible underlying mechanism of transcrip-
tional repression by overexpression and knockdown of SRA. Histone
acetyltransferase p300 has been described as an enhancer mark [32]
and as a co-activator for Notch-mediated transcription [6]. In ChIP-
experiments using SRA knockdown Beko cells, p300 recruitment isFig. 5. Recruitment of histoneacetyltransferase p300 is lost upon either knockdown or
overexpression of SRA. ChIP analysiswas performedwith anα-p300 antibody at enhancer
elements of Notch target genes. A. Pre-T-cell line Beko was infected with shRNA SRA in
order to downregulate SRA expression. Chromatin-immunoprecipitation (ChIP) experi-
ments using anti-p300 antibodies (no antibody as mock control) were performed in
Beko cells treated with SRA speciﬁc shRNA or scrambled shRNA. p300 was signiﬁcantly
enriched around the enhancer elements of Notch target genes preTCRα+10.5 kb,
Hes1+0.6 kb and CD25-26 kb (light gray bars) and lost upon SRA knockdown (dark
gray bars). ChIP was normalized to the GAPDH promoter and no occupancy was found
at Hes1 region +2.4 kb (control). B. Pre-T-cell line Beko was infected with a plasmid for
SRA overexpression. ChIP experiments using anti-p300 antibodies (no antibody as mock
control) were performed in the absence (empty vector, eV) or after SRA overexpression
(SRA plasmid). p300 was signiﬁcantly enriched around the enhancer elements of Notch
target genes preTCRα+10.5 kb, Hes1+0.6 kb and CD25-26 kb (light gray bars) and
erased upon SRA overexpression (OE) (dark gray bars). ChIP was normalized to the
GAPDH promoter and no occupancy was found at Hes1 region +2.4 kb (control). Data
presented as means±SD of three independent experiments. C. In ChIP experiments
using α-p300 antibodies, the recruitment of p300 to enhancer elements of Notch target
genes preTCRα+10.5 kb, Hes1+0.6 kb and CD25-26 kb is abrogated upon 24 hour GSI
treatment (dark gray bars). No antibody was used as mock control. ChIP was normalized
to the GAPDH promoter and no occupancy was found at Hes1 region +2.4 kb (control).
Data presented asmeans±SD of three independent experiments measured in duplicates.
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lesser extent at CD25 (Fig. 5A). Interestingly, loss of p300 recruitment
is also reduced after overexpression of SRA (Fig. 5B) which is in line
with the downregulation of Notch target genes (see Fig. 4G and H).
The loss of binding of p300 at Notch target genes is comparable to
what we observe after Notch pathway inhibition by GSI (Fig. 5C). Sur-
prisingly, this is not the case in Ddx5 knockdown cells (Fig. S4); see
also discussion.
Histone acetylation at lysine 18 of histoneH3 (H3K18), a knownmark
for p300 acetylation [33], is also reduced upon either overexpression or
knockdown of SRA (Fig. S5A and B). Thus, noncoding RNA SRAmediates
p300 recruitment and H3K18 acetylation at Notch target genes.4. Discussion
Activation of the Notch pathway is implicated in several disease
states, including acute T-cell lymphoblastic leukemia [10] and chronic
lymphocytic leukemia [34]. Thus, ﬁnding new targets for the Notch
coactivator complex is desirable to develop Notch inhibitors or mod-
iﬁers. In this regard enzymes in particular are of great interest. Our
identiﬁcation of RNA helicase Ddx5 as coactivator of Notch target
genes suggests that inhibitors of Ddx5 could be used pharmacologi-
cally to target Notch-mediated diseases. In a recent publication by
Dr. L. Wu and colleagues, Ddx5 has been shown to directly interact
with MAML1, a well-known cofactor for Notch [35]. These results
are in agreement with our ChIP results showing that Ddx5 recruit-
ment is Notch-dependent. The data presented here shows that Ddx5
also directly interacts with the transcription factor RBP-J, suggesting
that there are at least two docking sites in the Notch-coactivator com-
plex for Ddx5.We clearly ﬁndDdx5 to interactwith RBP-J in the absence
of Notch activation, i.e. pulling down RBP-J followed by mass spectrom-
etry (data not shown). In in vivo ChIP experiments Ddx5 is found at
target genes exclusively in a Notch-dependent manner. This might
be due to other coactivator components like Mastermind. However,
in Notch inactive B-cells we do observe RBP-J dependence of Ddx5
occupancy at Notch target genes. Together, this suggests that there
is also a Notch-independent mechanism of RBP-J/Ddx5 interaction.
It will be highly interesting to further investigate the role of
non-coding RNAs in the activation of Notch target genes. We show
that the long non-coding RNA SRA plays a key role in the regulation
of several Notch target genes. Moreover, it would be of interest to fol-
low the dynamic recruitment of SRA at Notch target genes; however,
techniques from such experiments have yet to be developed.
In the case of knockdown or overexpression of the coactivator SRA
the effects on Notch target genes are relatively broad, and p300 recruit-
ment at Notch target genes is severely affected. In the case of Ddx5
knockdown only a subset of Notch target genes (Hes1, preTCRα and
Notch1) are downregulated. Expression of other Notch target genes
like Dtx1, NRARP and Hey1 remain unchanged. Surprisingly, recruit-
ment of the acetyltransferase p300 remains unaffected at down-
regulated genes. Since Ddx5 not only regulates p300 recruitment and
histone acetylation, but also post-transcriptional events such as splic-
ing, nuclear export or stabilization of RNA [11], one possible scenario
is that the homologous RNA helicase Ddx17 can partially compensate
for lack of Ddx5, but importantly, not for SRA. This is supported by a
study from Janknecht and colleagues showing that Ddx17 interacts
with p300 [17]. Thus, themechanism for how speciﬁcity at Notch target
genes is achieved remains an open and demanding question.
Recently, Fuller-Pace and colleagues published a study about Ddx5/
p68 conditional knockout mice [36]. Here, a strong effect on p53-
dependent p21 expression and cell-cycle arrest after DNA damage is
observed. It will be interesting to see the effect of Ddx5-deletion in he-
matopoiesis, especially during early T-cell development.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2013.01.032.Acknowledgments
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